; (B) recommend a policy and process for mandatory public disclosure of emissions and climate risk relating to drugs and devices; (C) recommend a policy for oversight of disclosures to ensure accuracy and transparency of emissions reporting as described in subparagraph (B), and to ensure that patient safety and necessary access is maintained; (D) develop methods to disseminate information to clinicians for low environmental impact options for clinically equivalent treatment options; (E) develop suggestions for the reduction of emissions by drug and device manufacturers without harming or risking patient safety; and (F) provide technical assistance and establish partnerships to facilitate lower emissions design and manufacture of comparable drugs and comparable devices. (3) Membership The task force established under paragraph (1) shall be composed of the following: (A) 3 representatives of the Food and Drug Administration, appointed by the Commissioner. (B) 3 representatives of the Environmental Protection Agency, appointed by the Administrator of the Environmental Protection Agency. (C) 3 representatives of the Office of Climate Change and Health Equity of the Department of Health and Human Services, appointed by the Secretary. (b) Regulations Not later than 1 year after the date of enactment of the Green New Deal for Health Act , the Secretary shall promulgate regulations to— (1) establish mandatory climate risk disclosure and transparency policies for drugs and devices approved, licensed, or cleared under section 505, 510(k), 513(f)(2), or 515 of this Act or section 351 of the Public Health Service Act